Clinical Efficacy and Brain Volumetric Changes in Pediatric-Onset Multiple Sclerosis Under Teriflunomide Treatment.
Findings provide exploratory evidence of longitudinal volumetric change in a teriflunomide-treated POMS cohort despite residual clinical disease activity, and should be interpreted cautiously and warrant confirmation in larger, controlled longitudinal studies.